{
    "id": 2130,
    "fullName": "JAK2 Y931C",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "JAK2 Y931C lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). Y931C results in increased phosphorylation of Jak2 and Stat5, is transforming in cell culture, and confers resistance to Jak inhibitors (PMID: 21393331, PMID: 26419724).",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 4779,
                    "pubMedId": 26419724,
                    "title": "Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26419724"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3717,
        "geneSymbol": "JAK2",
        "terms": [
            "JAK2",
            "JTK10",
            "THCYT3"
        ]
    },
    "variant": "Y931C",
    "createDate": "10/07/2014",
    "updateDate": "10/23/2019",
    "referenceTranscriptCoordinates": {
        "id": 151052,
        "transcript": "NM_004972",
        "gDna": "chr9:g.5090476A>G",
        "cDna": "c.2792A>G",
        "protein": "p.Y931C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1161,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2064,
                "profileName": "JAK2 Y931C"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21165,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 2065,
                "profileName": "JAK2 V617F JAK2 Y931C"
            },
            "therapy": {
                "id": 823,
                "therapyName": "Momelotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21168,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Lestaurtinib (CEP-701) in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 2065,
                "profileName": "JAK2 V617F JAK2 Y931C"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21166,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 2065,
                "profileName": "JAK2 V617F JAK2 Y931C"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21163,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 2065,
                "profileName": "JAK2 V617F JAK2 Y931C"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21171,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing the JAK2 V617F and JAK2 Y931C double mutation demonstrated resistance to Inrebic (fedratinib) in culture (PMID: 21926964).",
            "molecularProfile": {
                "id": 2065,
                "profileName": "JAK2 V617F JAK2 Y931C"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3038,
                    "pubMedId": 21926964,
                    "title": "Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21926964"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1162,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",
            "molecularProfile": {
                "id": 2065,
                "profileName": "JAK2 V617F JAK2 Y931C"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 908,
                    "pubMedId": 21393331,
                    "title": "Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21393331"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20494,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inrebic (fedratinib) treatment inhibited colony formation and proliferation of transformed cells expressing JAK2 V617F and Y931C in culture (PMID: 26419724).",
            "molecularProfile": {
                "id": 2065,
                "profileName": "JAK2 V617F JAK2 Y931C"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4779,
                    "pubMedId": 26419724,
                    "title": "Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26419724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20496,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and S1025C demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724).",
            "molecularProfile": {
                "id": 35209,
                "profileName": "JAK2 V617F JAK2 Y931C JAK2 S1025C"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4779,
                    "pubMedId": 26419724,
                    "title": "Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26419724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20497,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and Y1045W demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724).",
            "molecularProfile": {
                "id": 35210,
                "profileName": "JAK2 V617F JAK2 Y931C JAK2 Y1045W"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4779,
                    "pubMedId": 26419724,
                    "title": "Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26419724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20498,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and F1061W demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724).",
            "molecularProfile": {
                "id": 35211,
                "profileName": "JAK2 V617F JAK2 Y931C JAK2 F1061W"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4779,
                    "pubMedId": 26419724,
                    "title": "Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26419724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20499,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing JAK2 V617F, Y931C and V1075F demonstrated resistance to Inrebic (fedratinib) treatment in culture (PMID: 26419724).",
            "molecularProfile": {
                "id": 35212,
                "profileName": "JAK2 V617F JAK2 Y931C JAK2 V1075F"
            },
            "therapy": {
                "id": 911,
                "therapyName": "Fedratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4779,
                    "pubMedId": 26419724,
                    "title": "Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26419724"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2064,
            "profileName": "JAK2 Y931C",
            "profileTreatmentApproaches": [
                {
                    "id": 5164,
                    "name": "JAK2 Inhibitor",
                    "profileName": "JAK2 Y931C"
                },
                {
                    "id": 5163,
                    "name": "JAK Inhibitor (Pan)",
                    "profileName": "JAK2 Y931C"
                }
            ]
        },
        {
            "id": 2065,
            "profileName": "JAK2 V617F JAK2 Y931C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35209,
            "profileName": "JAK2 V617F JAK2 Y931C JAK2 S1025C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35210,
            "profileName": "JAK2 V617F JAK2 Y931C JAK2 Y1045W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35211,
            "profileName": "JAK2 V617F JAK2 Y931C JAK2 F1061W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35212,
            "profileName": "JAK2 V617F JAK2 Y931C JAK2 V1075F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 151050,
            "transcript": "NM_001322195",
            "gDna": "chr9:g.5090476A>G",
            "cDna": "c.2792A>G",
            "protein": "p.Y931C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 151049,
            "transcript": "NM_001322194",
            "gDna": "chr9:g.5090476A>G",
            "cDna": "c.2792A>G",
            "protein": "p.Y931C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 151052,
            "transcript": "NM_004972",
            "gDna": "chr9:g.5090476A>G",
            "cDna": "c.2792A>G",
            "protein": "p.Y931C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 151051,
            "transcript": "NM_001322196",
            "gDna": "chr9:g.5090476A>G",
            "cDna": "c.2792A>G",
            "protein": "p.Y931C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}